Life Sciences Strategy and Innovation

Connecting Clinical Innovation with Commercial Success: An Example from Multiple Myeloma 

In the past decade, advancements in scientific research and digital innovation have revolutionized healthcare, with patients, caregivers and clinicians alike reaping the benefits. At the same time, traditional clinical research has been augmented by new and expanded data sets that have accelerated the ability to identify diseases with precision, leading to targeted and effective treatments. Consider breast cancer:

The extraordinary clinical advancements seen in breast cancer are mirrored in other disease categories, most notably multiple myeloma (MM), where clinical improvements go beyond quality of life to possible cures. And while these advancements hint at a bright future for patient outcomes, a noticeable disparity remains.

So, what can be done to bridge the gap?

Using MM as an example, this white paper explores the evolution of current biopharmaceutical commercial models. By addressing key considerations essential for every healthcare leader, we illustrate the profound impact of integrating digital assets — from reshaping commercial frameworks and bolstering patient support to deepening clinician engagement and markedly enhancing health outcomes.

Download our white paper now.